Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

NCT04104607 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT04104607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04104607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1
Overall status
Recruiting
Start date
November 15, 2019
Completion date
December 31, 2025
Enrollment
86 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostatic cancer